Funding for this research was provided by:
National Natural Science Foundation of China (82000588, 82070604, 81900567)
the “Chenguang Program” supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission
the Chinese foundation for hepatitis prevention and control-TianQing liver disease research fund subject (TQGB20210021)
Shanghai Municipal Key Clinical Specialty (shslczdzk01103)
Received: 24 February 2022
Accepted: 5 May 2022
First Online: 16 May 2022
: All patients’ identifers were removed from the data before extraction from the database. No personal identifers were used during analysis and presentation. This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Review Committees at Ruijin hospital (2018-LLS-162).
: Not applicable.
: The authors declare that they have no competing interests.